Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol

International Journal of Pharmaceutics

Volumn 377, Issue 1-2, 2009, Pages 128-134

  Gao, Yanli ^a   Liang, Jinying ^b   Liu, Jianping ^a   Xiao, Yan ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

7 day patch; Contraception; Ethinylestradiol; Gestodene; Transdermal

Indexed keywords

ETHINYLESTRADIOL PLUS GESTODENE; POLYVINYL ALCOHOL; POVIDONE; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SKIN PENETRATION; SUSTAINED DRUG RELEASE; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ETHINYL ESTRADIOL; MICE; NORPREGNENES; PERMEABILITY; POLYMERS; RABBITS; SKIN ABSORPTION; TIME FACTORS;

EID: 67649649927     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.05.017     Document Type: Article

References (35)

1. Aarti N., Louk A.R.M.P., Russell O.P., and Richard H.G. Mechanism of oleic acid-induced skin permeation enhancement in vivo in humans. Control. Release 37 (1995) 299-306
2. Archer D.F., Bigrigg A., and Smallwood G.H. Assessment of compliance with a weekly contraceptive patch (Ortho EvraTM/EvraTM) among North American women. Fertil. Steril. (2002) 27-31
3. Archer D.F., Cullins V., Creasy G.W., and Fisher A.C. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficiency. Contraception 69 (2002) 189-195
4. Babu R.J., and Pandit J.K. Effect of permeation enhancers on the transdermal delivery of Bupranolol through rat skin. Drug Deliv. 12 (2005) 165-196
5. Back D.J., Bates M., and Breckenridge A.M. The pharmacokinetics of levonorgestrel and ethinylestradiol in women--studies with Ovran and Ovranette. Contraception 23 (1981) 229-239
6. Back D.J., Madden S., and Orme M.L. Gastrointestinal metabolism of contraceptive steroids. Am. J. Obstet. Gynecol. 163 (1990) 2138-2145
7. Bajos N., Leridon H., Goulard H., Oustry P., Job-Spira N., and Goup COCON. Contraception: from accessibility to efficiency. Hum. Reprod. 18 (2003) 994-999
8. Barry B.W. Lipid-protein-partitioning theory of skin permeation enhancement. Control. Release 15 (1991) 237-248
9. Biana G., and Elka T. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv. Drug Deliv. Rev. 59 (2007) 1152-1161
10. Boelsma E., Tanojo H., Bodde H.E., and Ponec M. Assessment of the potential irritancy of oleic acid on human skin: evaluation in vitro and in vivo. Toxicol. In Vitro 10 (1996) 729-742
11. Chen, G.S., Wang, Q., Ye, J.C., 1995. 7-day transdermal delivery system for estradiol. CN Patent 1 112 421A, 29 November.
12. Chien, Y.W., Chien, T.Y., Huang, Y.C., 1988. Transdermal estrogen/progestin dosage unit, system and process. EP Patent 0 275 716A, 27 July.
13. Davis A.F., and Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int. J. Pharm. 76 (1991) 1-8
14. Draize J.H., Woodard G., and Calvery H.O. Methods for the study of irritation and toxicity of substances applied to the skin and mucous membrane. J. Pharmacol. Exp. Ther. 82 (1944) 377-390
15. Dominique P., Annie S.R., and Michel J. Oral contraception and cardiovascular risk factors during adolescence. Contraception 62 (2000) 113-116
16. Ferreira A.C.P., Montes M.B.A., Franceschini S.A., and Toloi M.R.T. Third-generation progestogen type influences hemostatic changes caused by oral contraceptives in Brazilian women. Contraception 64 (2001) 353-356
17. Friend D.R. Transdermal delivery of contraceptives. Drug Carrier Syst. 7 (1990) 149-186
18. Goodman M., and Barry B.W. Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique. Int. J. Pharm. 57 (1989) 29-40
19. Ines Z.S., Patrick F., Ulrich F., Schaefer, and Claus-Michael L. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. Control. Release 118 (2007) 196-203
20. Jenquin M.R., and McGinity J.W. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int. J. Pharm. 101 (1994) 23-34
21. Moser K., Kriwet K., Kalia Y.N., and Guy R.H. Enhanced skin permeation of a lipophilic drug using supersaturated formulations. Control. Release 73 (2001) 245-253
22. Mukherjee B., Mahapatra S., Gupta R., Patra B., Tiwari A., and Arora P. A comparison between povidone-ethylcellulose and providone-eudragit transdermal dexamethasone matrix patches based on in vitro skin permeation. Eur. J. Pharm. Biopharm. 59 (2005) 475-483
23. Padula C., Nicoli S., Colombo P., and Santi P. Single-layer transdermal film containing lidocaine: Modulation of drug release. Eur. J. Pharm. Biopharm. 66 (2007) 422-428
24. Pietrzak B., Bobrowska K., Jabiry-Zieniewicz Z., Kaminski P., Wielgos M., Pazik J., and Durlik M. Oral and transdermal hormonal contraception in women after kidney transplantation. Transplant. Proc. 139 (2007) 2759-2762
25. Raghavan S.L., Kiepfer B., Davis A.F., Kazarian S.G., and Hadgraft J. Membrane transport of hydrocortisone acetate from supersaturated solutions: the role of polymers. Int. J. Pharm. 221 (2001) 95-105
26. Régine S.W. Transdermal application of steroid hormones for contraception. J. Steroid Biochem. 53 (1995) 247-251
27. Régine S.W. Delivery options for contraceptives. Rev. Drug Discov. 10 (2005) 977-985
28. Rosenberg M.J., Waugh M.S., and Burnhill M.S. Compliance, counseling and satisfaction with oral contraceptives: a prospective evluation. Int. Fam. Plan Perspect. 30 (1998) 89-92
29. Sunanda G. Non-oral hormonal contraception. Curr. Obstet. Gynaecol. 13 (2003) 30-37
30. Terry W., Begüm O., John K.J., and Frank Z.S. Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins. Contraception 74 (2006) 293-296
31. Ulrike F., Emily, Slater P., and Karl-Heinrich F. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception 51 (1995) 45-52
32. Wolfgang U., Dan A., Alan A., Peter K., Siegfried S., Jacques B., Alan C.F., and Michael P. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur. J. Obstet. Gynecol. Reprod. Biol. 121 (2005) 202-210
33. Zhan X.P., Tang G.C., Chen S.J., and Mao Z.M. A new copolymer membrane controlling clonidine linear release in a transderal drug delivery system. Int. J. Pharm. 322 (2006) 1-5
34. Zhang, J.S., Dong, J., 1994. The preparation and application of a controlled-release TDDS. CN Patent 1 094 972A, 16 November.
35. Zurdo S.I., Franke P., Schaefer U.F., and Lehr C.M. Development and characterization of film forming polymeric solutions for skin drug delivery. Eur. J. Pharm. Biopharm. 65 (2007) 111-121